Overview

MEF2D is altered in 0.03% of all cancers with invasive breast carcinoma, pancreatic adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, and diffuse glioma having the greatest prevalence of alterations [3].

The most common alterations in MEF2D are MEF2D-SS18 Fusion (0.05%), MEF2D-CSF1R Fusion (0.06%), and MEF2D-NTRK1 Fusion (0.09%) [3].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.